CA IX Inhibition by a Sulfonamide Compound: A Therapeutic Approach Against Breast Cancer
Chemistry & Biodiversity · 2026-03 · 23 (3)
DOI: 10.1002/cbdv.202501618 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry & Biodiversity, online erschienen am 13.03.2026. Verfasst von Sükrü Akmese und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Biochemistry, Medical Faculty, Harran University, Sanlıurfa, Turkey. Hauptthemen laut MEDLINE: Sulfonamides, Carbonic Anhydrase IX, Breast Neoplasms, Carbonic Anhydrase Inhibitors. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Harran University Scientific Research Projects Coordination Unit.
Abstract (Originalsprache)
Carbonic anhydrase IX (CA IX) is overexpressed in many solid tumors, contributing to cancer cell proliferation, survival, invasion, and metastasis. Sulfonamide‐based compounds have emerged as potential anticancer agents by inhibiting this enzyme. In this study, we investigated the anticancer potential of a previously synthesized sulfonamide derivative, MMH‐I, focusing on its CA IX‐targeted activity and therapeutic efficacy in both in vitro and in vivo models of breast cancer. Cytotoxicity was assessed using MTT assays in 4T1 breast cancer cells, while apoptosis was evaluated by acridine orange/ethidium bromide staining and Annexin V detection. In vivo studies analyzed tumor tissues for CA IX expression, as well as Vimentin, E‐Cadherin, and Caspase‐3 levels. H&E staining and plasma metabolomic analysis were performed to assess tissue morphology and metabolic alterations. The compound significantly reduced tumor volume, induced apoptosis, and altered cancer‐related gene expression and metabolic profiles. Overall, this study provides a detailed in vivo and metabolic evaluation of MMH‐I in breast cancer, highlighting its potential as a CA IX–targeted therapeutic candidate and supporting further investigation of sulfonamide‐based combination strategies against hypoxic tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Biochemistry, Medical Faculty, Harran University, Sanlıurfa, Turkey.
- Medical Promotion and Marketing Program, Vocational School of Health Services, Harran University, Sanliurfa, Turkey.
- Department Of Medical Biochemistry, Medical Faculty, Inonu University, Malatya, Turkey.
- Department of Chemistry, Faculty of Arts and Sciences, Harran University, Sanlıurfa, Turkey.
- Department of Pathology, Medical Faculty, Harran University, Şanlıurfa, Turkey.
- Dialysis program, Health Services Vocational School, Harran University, Sanlıurfa, Turkey.
ORCID-Profile: Sükrü Akmese, Ebru Temiz, Elif Gürel, Ismail Koyuncu, Mustafa Durgun, Muhammet Emin Guldur, Kadir Egi, Beyza Ozerol
Förderung
- Harran University Scientific Research Projects Coordination Unit
Zitieren
APA
Akmese, S., Temiz, E., Gürel, E., Koyuncu, I., Durgun, M., Guldur, M. E., Egi, K., & Ozerol, B. (2026). CA IX Inhibition by a Sulfonamide Compound: A Therapeutic Approach Against Breast Cancer. Chemistry & Biodiversity, 23(3). https://doi.org/10.1002/cbdv.202501618
Vancouver
Akmese S, Temiz E, Gürel E, Koyuncu I, Durgun M, Guldur ME, et al. CA IX Inhibition by a Sulfonamide Compound: A Therapeutic Approach Against Breast Cancer. Chemistry & Biodiversity. 2026;23(3). doi:10.1002/cbdv.202501618
BibTeX
@article{Akmese2026,
author = {Akmese, Sükrü and Temiz, Ebru and Gürel, Elif and Koyuncu, Ismail and Durgun, Mustafa and Guldur, Muhammet Emin and Egi, Kadir and Ozerol, Beyza},
title = {CA IX Inhibition by a Sulfonamide Compound: A Therapeutic Approach Against Breast Cancer},
journal = {Chemistry & Biodiversity},
year = {2026},
volume = {23},
number = {3},
doi = {10.1002/cbdv.202501618}
}
EUVIMED